Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure

Cardiovascular Drugs and Therapy

Volumn 30, Issue 6, 2016, Pages 599-609

  Pellicori, Pierpaolo ^a   Cleland, John G F ^a   Zhang, Jufen ^a   Kallvikbacka Bennett, Anna ^a   Urbinati, Alessia ^a   Shah, Parin ^a   Kazmi, Syed ^a   Clark, Andrew L ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Congestion; Heart failure; Loop diuretic; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; FUROSEMIDE; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPH; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VOLUME; HUMAN; HYPONATREMIA; KIDNEY DYSFUNCTION; LUNG PRESSURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA; PRIORITY JOURNAL; PROGNOSIS; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFECTS; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; INFERIOR CAVA VEIN; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DIURETICS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; TREATMENT OUTCOME; VENA CAVA, INFERIOR; VENTRICULAR FUNCTION, LEFT;

EID: 84994222170     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-016-6697-7     Document Type: Article

References (33)

1. Damy T, Kallvikbacka-Bennett A, Zhang J, et al. Does the physical examination still have a role in patients with suspected heart failure? Eur J Heart Fail. 2011;13:1340–8.
2. Shoaib A, Waleed M, Khan S, et al. Breathlessness at rest is not the dominant presentation of patients admitted with heart failure. Eur J Heart Fail. 2014;16:1283–91.
3. Pellicori P, Kallvikbacka-Bennett A, Dierckx R, et al. Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure. Heart. 2015;101:1149–58.
4. Pellicori P, Kallvikbacka-Bennett A, Khaleva O, et al. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification? Int J Card Imaging. 2014;30:69–79.
5. Pellicori P, Carubelli V, Zhang J, et al. IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging. 2013;6:16–28.
6. Pellicori P, Joseph AC, Zhang J, et al. The relationship of QRS morphology with cardiac structure and function in patients with heart failure. Clin Res Cardiol. 2015;104:935–45.
7. Cleland JG, Taylor J, Freemantle N, Goode KM, Rigby AS, Tendera M. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail. 2012;14:487–94.
8. Cleland JG, McMurray JJ, Kjekshus J, et al. CORONA study group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (controlled rosuvastatin multinational trial in heart failure). J Am Coll Cardiol. 2009;54:1850–9.
9. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22.
10. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1–6.
11. Stevenson LW, Nohria A, Mielniczuk L. Torrent or torment from the tubules? Challenge of the cardiorenal connections. J Am Coll Cardiol. 2005;45:2004–7.
12. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Studies of left ventricular dysfunction. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.
13. Neuberg GW, Miller AB, O'Connor CM, et al. PRAISE investigators. Prospective randomized amlodipine survival evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–8.
14. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–64.
15. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Committee for practice guidelines (CPG).ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933–89.
16. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for practice guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.
17. Pellicori P, Zhang J, Lukaschuk E, et al. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. Eur Heart J. 2015;36:733–42.
18. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.e14.
19. Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:935–44.
20. Cleland JG, Dargie HJ, East BW, et al. Total body and serum electrolyte composition in heart failure: the effects of captopril. Eur Heart J. 1985;6:681–8.
21. Cleland JG, Carubelli V, Castiello T, Yassin A, Pellicori P, Antony R. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev. 2012;17:133–49.
22. Hanberg JS, Rao V, Ter Maaten JM, et al. Hypochloremia and Diuretic Resistance in Heart Failure: Mechanistic Insights. Circ Heart Fail. 2016;9:e003180.
23. Ter Maaten JM, Damman K, Hanberg JS, et al. Hypochloremia, diuretic resistance, and outcome in patients with acute heart failure. Circ Heart Fail. 2016;9:e003109.
24. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev 2012;15; 2:CD003838.
25. Damman K, Kjekshus J, Wikstrand J, et al. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2016;18:328–36.
26. Pfisterer M, Buser P, Rickli H, et al. TIME-CHF investigators. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA. 2009;301:383–92.
27. Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014;35:1559–67.
28. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol. 2007;49:1733–9.
29. Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol. 2009;55:53–60.
30. Abraham WT, Adamson PB, Bourge RC, et al. CHAMPION trial study group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–66.
31. Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987:709–11.
32. van Kraaij DJ, Jansen RW, Sweep FC, Hoefnagels WH. Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. Eur J Heart Fail. 2003;5:47–53.
33. Gupta S, Waywell C, Gandhi N, et al. The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction. Eur J Heart Fail. 2010;12:746–52.